Tuesday, 23 Jan 2018

You are here

Tildrakizumab, an IL-23 Inhibitor, is Successful in Plaque Psoriasis

Therapeutic options for cutaneous psoriasis (and psoriatic arthritis as well) are rapidly expanding.  Lancet has published the impressive results of two phase III trials of tildrakizumab, a IgG1 antibody against interleukin 23 p19, in patients with active chronic plaque psoriasis.

Two large randomised controlled studies, reSURFACE 1 and reSURFACE 2 enrolled  2062 adults with moderate-to-severe chronic plaque psoriasis with ≥10% body surface area involvement.

In reSURFACE 1, patients received tildrakizumab 200 mg, tildrakizumab 100 mg, or placebo and in reSURFACE 2 they received tildrakizumab 200 mg, tildrakizumab 100 mg, placebo, or etanercept 50 mg given subcutaneously at weeks 0 and 4 during part 1 of the studies and at week 16 during part 2.

In reSURFACE 1, at week 12, a PASI75 was acheived in 62% in the 200 mg group and 64% in the 100 mg group compared with 6% in the placebo group (p<0·0001 vs placebo).

In reSURFACE 2, a PASI75 was seen 66% in the 200 mg group, 61% in the 100 mg group, and 48% in the etanercept group compared with 6% in the placebo group.

Serious adverse events were similar and low in all groups in both trials, with only one death in reSURFACE 2.

These 2 large trials affirm the efficacy of tildrakizumab (an IL-23 inhibitor) in psoriasis and that responses were superior to placebo and etanercept in moderate-to-severe chronic plaque psoriasis patients. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Apremilast’s Rapid Onset in Psoriatic Arthritis

Monotherapy with apremilast (Otezla) among patients with psoriatic arthritis who were biologic-naive was significantly more effective than placebo as early as week 2 in a phase IIIb study. 

Salt Drives Gut-Brain Connection via IL-17

A study from Nature Neuroscience shows that a high salt diet may mediate neurovascular disease by altering microbiome and the expansion of TH17 cells in the small intestine, thereby increasing plasma interleukin-17 (IL-17) and its subsequent effects on endothelium in the brain.

MEASURE 3 Study - Anti-IL17 Benefits Persist in Spine Disease

Patients with ankylosing spondylitis (AS) have shown rapid and sustained responses to secukinumab (Cosentyx) in a third phase III trial that includes a higher dose of this anti-interleukin-17A monoclonal antibody, researchers reported.

Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA (Best of 2017)

In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA. 

Cardiac Disturbances Increased in Spondyloarthritis

A prospective Swedish study between 2001–2009 found a higher risk of aortic regurgitation, pacemaker, AV block and atrial fibrillation in SpA, AS, uSpA and PsA patients.